Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.